Skip to main content
main-content

Cardiology

Cardiology

01-09-2021 | Diabetes | News | Article

Telmisartan linked to reduced dementia risk in people with type 2 diabetes, hypertension

Study results suggest that telmisartan use in people with concomitant type 2 diabetes and hypertension is associated with a lower incidence of dementia and ischemic stroke compared with the use of other angiotensin receptor blockers.

29-08-2021 | Diabetes | News | Article

Empagliflozin has broad beneficial effect on HFpEF outcomes

Empagliflozin treatment produces significant reductions in the risk for a broad range of inpatient and outpatient heart failure outcomes in people with a preserved ejection fraction, shows further analysis of EMPEROR-Preserved.

29-08-2021 | Diabetes | News | Article

HF and CKD doubly dangerous for people with type 2 diabetes

Rates of hospitalization and mortality are increased in people with type 2 diabetes who also have heart failure or chronic kidney disease, and more so if they have both conditions, say researchers.

28-08-2021 | Diabetes | News | Article

FIGARO-DKD: Finerenone cardioprotective across broad range of renal risk

Finerenone protects against adverse cardiovascular outcomes in people with type 2 diabetes and mild or moderate chronic kidney disease, the FIGARO-DKD investigators have reported at the virtual ESC Congress 2021.

27-08-2021 | Diabetes | News | Article

EMPEROR-Preserved: A win for empagliflozin in HFpEF

Empagliflozin has become the first medication to demonstrate a clear protective effect in people with heart failure and preserved ejection fraction, report the EMPEROR-Preserved investigators.

27-08-2021 | Diabetes | News | Article

Dapagliflozin benefits wide range of people with CKD

Dapagliflozin reduces the risk for kidney failure, heart failure hospitalization, and death in people with chronic kidney disease, irrespective of their history of HF, DAPA-CKD study data show.

26-07-2021 | Rheumatology | News | Article

Observational data stress CV benefits of glucocorticoid tapering in RA

Steroid-naive patients with rheumatoid arthritis have a dose- and duration-dependent increased risk for cardiovascular events following glucocorticoid initiation, real-world study data show.

18-06-2021 | Diabetes | News | Article

Early polyneuropathy may be a risk factor for CVD

People with symptoms indicative of diabetic polyneuropathy near the time of type 2 diabetes diagnosis have a “markedly higher” risk for subsequent cardiovascular disease than those without, researchers report.

28-04-2021 | Oncology | News | Article

AHA issues statement on managing hormonal therapy-related CVD risks

The American Heart Association has released a consensus statement on the management of cardiovascular disease in patients receiving hormonal therapies for breast or prostate cancer.

28-04-2021 | Oncology | News | Article

Cardiovascular AEs of prostate cancer hormone therapies reported

An analysis of the FDA Adverse Event Reporting System has provided detailed insight into cardiovascular adverse events associated with different classes of androgen deprivation therapies.

22-04-2021 | Oncology | News | Article

Limited evidence to link antihypertensive use to cancer

An extensive meta-analysis of individual participant data has not found consistent evidence to indicate that antihypertensive use is associated with an increased risk for cancer.

04-02-2021 | Diabetes | News | Article

High CVD risk at type 2 diabetes diagnosis increasingly common

The proportion of people with new-onset type 2 diabetes who have high cardiovascular risk has increased consistently over time, with a particularly notable rise in the prevalence of cardiometabolic multimorbidity among young people, researchers report.

15-01-2021 | Diabetes | News | Article

SGLT2 inhibition may reduce myocardial extracellular volume

Treatment with the SGLT2 inhibitor empagliflozin is associated with a reduction in myocardial extracellular volume among individuals with type 2 diabetes and coronary artery disease, suggests an analysis of data from the EMPA-HEART CardioLink-6 trial.

08-01-2021 | Oncology | News | Article

Data suggest no causality between osimertinib use, cardiac AEs

A review of data from the osimertinib clinical trials program has not identified a causal relationship between the use of the EGFR–tyrosine kinase inhibitor and cardiotoxicity among patients with advanced non-small-cell lung cancer.

18-12-2020 | Cardiovascular | News | Article

DAPA-CKD: Dapagliflozin renoprotective regardless of underlying CKD etiology

A prespecified analysis of data from the DAPA-CKD trial suggests that add-on treatment with dapagliflozin slows decline in renal function among patients with chronic kidney disease irrespective of the underlying etiology.

18-12-2020 | Oncology | News | Article

Researchers call for increased awareness of cardiac events among ICI users

People receiving immune checkpoint inhibitor therapy for lung cancer or malignant melanoma have a significantly increased risk for cardiovascular events, observational study data show.

04-12-2020 | Rheumatology | News | Article

Even low-dose oral glucocorticoid use associated with increased CV risk

UK research has identified a “strong dose-dependent” association between oral glucocorticoid use and CVD risk among people with immune-mediated diseases, with an increased risk seen even at doses of less than 5 mg/day.

04-12-2020 | Diabetes | News | Article

EMPA-REG OUTCOME: Empagliflozin reduces total CV burden in type 2 diabetes

Empagliflozin reduces the total burden of cardiovascular complications and all-cause hospitalization in people with type 2 diabetes and atherosclerosis, show data from the EMPA-REG OUTCOME trial.

27-11-2020 | Diabetes | News | Article

Healthy lifestyle mitigates elevated heart disease risk in people with type 2 diabetes

People with type 2 diabetes have around a fourfold increased risk for heart disease relative to those without, but having a healthy lifestyle may lessen this risk, researchers report.

26-11-2020 | Diabetes | News | Article

Type 2 diabetes linked to increased CVD risk even without CV risk factors

The risk for cardiovascular disease is at least one-fifth higher in people with type 2 diabetes than in those without diabetes, even when risk factors are optimally controlled, study findings indicate.

Image Credits